The European Commission has set a provisional Dec. 3 deadline to decide on the deal.
India-based Sun Pharmaceutical Industries has asked EU regulators to approve its intended purchase of American rival Organon.
The European Commission has set a provisional Dec. 3 deadline to decide on the $11.75 billion deal.
Sun filed the deal on Wednesday, the EU regulator’s website showed. It announced in April the plan to buy all of Organon’s shares at $14 apiece. In a press release, Sun said it plans to fund the deal “through a combination of available cash resources and committed financing from banks”.
The acquisition has already been cleared in some countries, such as Morocco, Egypt and – according to the company – also in the US.
The transaction is being reviewed in Australia. There the companies have offered to give another company exclusive rights to sell ganirelix acetate in Australia to address a "competitive overlap," according to the Australian Competition & Consumer Commission.
Regulators in Australia said the companies also overlap in the supply of several medicines, including antidepressants, antipsychotics, migraine treatments and fertility drugs used in IVF.
If the transaction goes through, Sun expects to become among the top 25 global pharmaceutical companies and a top 3 company in global Women’s Health, with its own commercial platform.
Sun’s acquisition of Organon is also filed for review under the EU’s foreign subsidies regulation, with a Nov. 23 decision deadline and case file number FS.100376.
Source: MLex